New research indicates that individuals who stop using new weight-loss injections like semaglutide or tirzepatide may regain shed pounds far faster than those who stop traditional lifestyle plans.
Findings released in a prominent medical journal points out that while obese people can lose about a fifth of their total mass while on the medication, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"People buying such medications should be cognizant of the danger of rapid rebound weight gain when the medication concludes," stated researcher Dr. Susan Jebb.
This pace of recovery suggests a reversion to starting mass in about a year and a half.
Comparing Treatments
The analysis, which examined 37 of trials involving thousands of patients, contrasted the effects of GLP-1 agonists with older methods.
Researchers point out that people who lose weight through lifestyle changes alone typically experience a slower weight regain—approximately 100 grams monthly—after stopping.
Understanding the Rapid Rebound
Nutrition scientists propose the mode of action of the drugs explains the heightened rebound.
These medications copy a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Sustained high doses of the hormone levels far above than normal could lead to the system to generate a reduced amount of its endogenous GLP-1, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics expert.
"Discontinuation of this hormone supplement means appetite is no longer kept in check, making overeating a significant risk."
An Ongoing Disease?
Medical guidelines recommend the jabs for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Many experts say that, considering the high risk of weight regain, the therapy should be considered ongoing.
This view is echoed by pharmaceutical companies, who say that the results "emphasize the persistent nature of obesity," akin to managing diseases like high blood pressure.
User Testimonies
People who have discontinued the jabs report a sudden return of appetite.
"I experienced something activating and you're instantly starving," recalled a patient.
This challenge is worsened if users have not developed sustainable dietary or behavioural changes during therapy.
Widespread Interest
Figures indicate that millions of people in the UK have used these injections in the past year, with interest continuing to grow.
- Use is more common among women than males.
- The middle-aged demographic shows the highest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
In conclusion, experts emphasize that while these medications are effective tools for shedding pounds, they are not a standalone cure and maintained weight loss likely depends on ongoing lifestyle support.
